Forest Aerobid Non-CFC Asthma Inhaler Launch Expected In Fall, C0O Says
Executive Summary
Forest will launch its non-CFC version of the prescription asthma inhaler Aerobid (flunisolide) this fall, President and Chief Operating Officer Kenneth Goodman told analysts on a conference call Jan. 16.
You may also be interested in...
FDA Warns Two Contract Research Sites Over Protocol Violations
Comprehensive Clinical Research has made several personnel changes in response to an FDA inspection that resulted in a June 5 warning letter
FDA Warns Two Contract Research Sites Over Protocol Violations
Comprehensive Clinical Research has made several personnel changes in response to an FDA inspection that resulted in a June 5 warning letter
Forest Phase III For Constipation-Predominant IBS To Begin In Late 2001
Forest will start Phase III trials for dexgloxiglumide in constipation-predominant irritable bowel syndrome before year-end.